Ketorz solution for infection. 30mg/ml fl. 1 ml No. 10

Ketorz – nonsteroid anti-inflammatory and antirheumatic drug.

quickly at moderate and severe postoperative pains.

only in hospital. The maximum duration of application is 2 days.

Structure

• active ingredient: ketorolak (ketorolac);
ketorolaka of a trometamin of 30 mg contains
• 1 ml of solution;
• other components: sodium chloride; citric acid, monohydrate; waterless ethanol; water for injections.

Ketorolak is contraindicated to

Contraindication

• to patients at whom reactions of hypersensitivity to a ketorolak were observed earlier to any of excipients or NPVS and patients with allergic reactions to aspirin, or other inhibitors of synthesis of prostaglandins in the anamnesis (at such patients heavy anaphylactic reactions were observed). Such reactions included asthma, rhinitis, a Quincke's disease or a small tortoiseshell;
• to patients with bronchial asthma in the anamnesis;
• to children up to 16 years;
• to patients with an active round ulcer, with recent gastrointestinal bleeding, a peptic ulcer or perforation in the anamnesis;
• as well as other NPVS, to patients with heavy heart failure, a liver failure and a renal failure;
• to patients with a moderate or heavy renal failure (creatinine level in blood serum more than 160 µmol/l) or to patients with risk of developing a renal failure owing to reduction of volume of liquid or dehydration;
• during pregnancy, during the fights and childbirth; during feeding by a breast;
• as preventive anesthetic before operation because of oppression of aggregation of platelets and during operation because of the increased risk of bleeding;
• for neuroaxial (epidural or intrathecal) introductions through alcohol content;
• in a combination with okspentifiliny;
• simultaneous treatment with probenetsidy or lithium salts;
• to patients with a full or partial syndrome of nasal polyps, a Quincke's disease or a bronchospasm;

Side reactions

from digestive tract. Most often undesirable observed side reactions are violations of digestive tract. There can be a round ulcer, ulcers, perforation or bleeding from digestive tract, sometimes with a lethal outcome, especially at patients of advanced age. Reported about: nausea, dyspepsia, pain/discomfort in a stomach, a hammer, vomiting blood, stomatitis, a stomacace, an eructation, a meteorism, an esophagitis, a digestive tract ulcer, rectal bleeding, pancreatitis, feeling of dryness in, exacerbation of colitis or Crohn's disease Less often observed gastritis.

an infection. Aseptic meningitis (especially at patients with the existing autoimmune disorders, such as hard currency, the mixed diseases of connective tissue), with such symptoms as constraint of muscles of a neck, a headache, nausea, vomiting, fever or a disorientation.

from blood and lymphatic system. Thrombocytopenia. Besides, the neutropenia, the Agranulocytosis, aplastic anemia and hemolytic anemia are observed purple.

from the immune system. An anaphylaxis, anaphylactoid reactions, anaphylactoid reactions similar to an anaphylaxis which can have a lethal consequence, reactions of hypersensitivity, such as bronchospasm, inflows, rash, hypotonia, laryngeal edema.

at persons with a Quincke's disease, bronkhospastichesky reactions in the anamnesis (for example, with asthma or polyps in a nose).

by

for an intramuscular or bolyusny injection.

Bolyusny intravenous administrations have to continue not less than 15 seconds. Drug should not be used for epidural or spinal introduction.

Speed of achievement of analgesic effect at intramuscular (in oil) and intravenous (in / c) introduction is identical

and is about 30 minutes, the maximum intensity of an analgesia comes within 1–2 hours. The average duration of anesthesia is 4-6 hours.

Adult

Recommended initial dose of a ketorolak of a trometamin, solution for injections, makes 10 mg with the subsequent introduction on 10-30 mg each 4-6 hours if necessary. At the beginning of the postoperative period, if necessary, it is possible to enter medicine each 2 hours. It is necessary to appoint a minimal effective dose. The general daily dose should not exceed 90 mg for patients of young age, 60 mg for patients of advanced age, patients with a renal failure and with a body weight less than 50 kg. The maximum duration of treatment should not exceed 2 days.

to

Feature of application

Use during pregnancy or feeding by a breast

Due to the proved influence of NPVS on the cardiovascular system of a fruit (early closing of an arterial channel), ketorolak it is contraindicated during pregnancy, fights and childbirth.

It was shown that ketorolak and its metabolites get to a fruit and to milk of animals. In low concentration ketorolak it was found in breast milk of the person therefore he is contraindicated for nursing mothers.

Safety and efficiency of use of medicine are not established to children by

therefore ketorolak children are not recommended to apply up to 16 years.

Ability to influence speed of response at control of motor transport or other mechanisms

At some patients can be observed by

dizziness, drowsiness, fatigue, a disorder of vision, a headache, vertigo, insomnia or a depression after application of a ketorolak. If such violations are observed, patients should not steer vehicles or work with mechanisms.

Overdose

Symptoms and signs

One-time overdose ketorolaky at different times led

to an abdominal pain, nausea, vomiting, a hyperventilation, round ulcers and/or erosive gastritis and dysfunction of kidneys which passed after the termination of administration of drug.

gastrointestinal bleeding Can arise. Arterial hypertension, OPN, respiratory depression and a coma after reception of NPVS can be observed though such symptoms arise seldom.

were Also observed by

: a headache, pain in epigastriums, a disorientation, excitement, drowsiness, dizziness, sonitus and a syncope.

to

It was reported about exceptional cases of diarrhea and single convulsions.

to

It was reported about development of anaphylactoid reactions which can arise also at overdose.

Treatment

Patients have to receive the symptomatic treatment and treatment supporting the vital functions after overdose of NPVS. Specific antidote is absent. Dialysis does not lead to significant removal of a ketorolak from blood because of high linking with proteins. Within 1 hour after use of medicine in potentially toxic doses activated carbon or gastric lavage as therapy of adult patients at threat of life can be applied.

to

Besides, it is necessary to provide the corresponding diuresis. Not less than 4 hours after reception should be watched carefully the patient, to control functions of a liver and kidneys. When developing repeated or long spasms the treatment by diazepam intravenously is recommended. Application of other therapeutic measures depending on a clinical condition of the patient is also possible.

Storage conditions

to Store

in original packing for protection against light at a temperature not over 25 ºС.

to Store

out of children's reach.